[go: up one dir, main page]

US20050187213A1 - Meloxicam for the treatment of respiratory diseases in pigs - Google Patents

Meloxicam for the treatment of respiratory diseases in pigs Download PDF

Info

Publication number
US20050187213A1
US20050187213A1 US11/047,920 US4792005A US2005187213A1 US 20050187213 A1 US20050187213 A1 US 20050187213A1 US 4792005 A US4792005 A US 4792005A US 2005187213 A1 US2005187213 A1 US 2005187213A1
Authority
US
United States
Prior art keywords
meloxicam
pharmaceutically acceptable
acceptable salt
disease
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/047,920
Other languages
English (en)
Inventor
Ingo Lang
Ioannis Papatsas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH filed Critical Boehringer Ingelheim Vetmedica GmbH
Assigned to BOEHRINGER INGELHEIM VETMEDICA GMBH reassignment BOEHRINGER INGELHEIM VETMEDICA GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LANG, INGO, PAPATSAS, IOANNIS
Publication of US20050187213A1 publication Critical patent/US20050187213A1/en
Priority to US12/114,509 priority Critical patent/US20080280840A1/en
Priority to US14/183,744 priority patent/US20140179639A1/en
Priority to US15/908,470 priority patent/US10548901B2/en
Priority to US16/719,681 priority patent/US11083731B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in pigs.
  • Respiratory disease in pigs belongs to the most important health problems in swine production. Porcine respiratory disease is primarily caused by infectious agents, but environmental factors have a strong influence.
  • the relevant pathogens include mycoplasmas, bacteria, and viruses (e.g., G. Christensen, V. Sorensen, and J. Mousing, Diseases of the Respiratory System, In: Diseases of Swine, B. E. Straw, S. D'Allaire, W. L. Mengeling, & D. J. Taylor (eds), Iowa State University Press, Ames, Iowa (1999) pp. 913-940).
  • porcine respiratory disease The most important measures for the control of porcine respiratory disease are to improve herd management and housing conditions and introduce a vaccination program. However, if pigs have developed respiratory disease, they have to be treated.
  • cyclooxygenase-2 plays a relevant role in the pathophysiology of porcine pleuropneumonia caused by Actinobacillus pleuropneumoniae.
  • Isolated porcine alveolar macrophages increase their COX-2 activity after exposure to Actinobacillus pleuropneumoniae (W. S. Cho & C. Chae, In vitro Effects of Actinobacillus pleuropneumoniae on Inducible Nitric Oxide Synthase and Cyclooxygenase- 2 in Porcine Alveolar Macrophages, Am J Vet Res 64, (2003) pp. 1514-1518).
  • in situ hybridization W. S. Cho & C.
  • acetylsalicylic acid can be used for the treatment of pigs with respiratory disease.
  • aspirin acetylsalicylic acid
  • Ketoprofen and, to a lesser extent, flunixin decrease fever induced by experimental infection with Actinobacillus pleuropneumoniae (J. M. Swinkels, A. Pijpers, J. C. Vernooy, A. Van Nes, & J. H.
  • Ketoprofen was further tested in a controlled, blinded clinical field study (M. F. De Jong, O. Sampimon, J. P. Arnaud, G. Theunissen, G. Groenland, & P. J. Werf, A Clinical Study with a Non Steroid Antiinflammatory Drug, 14, (1996) 659 IPVS). In this study, ketoprofen had no effect on clinical score, relapse, or cure rate.
  • Meloxicam is a non-steroidal anti-inflammatory compound that belongs to the oxicam class and exerts potent anti-inflammatory, anti-exudative, and anti-pyretic activity.
  • the efficacy of meloxicam as an adjunctive therapy in the treatment of respiratory infections in cattle has been widely proven.
  • Recently meloxicam was approved for the treatment of MMA (A. Hirsch et al., J Vet Pharmacol Therap 26 (2003) pp. 355-360) and locomotor disorders in pigs (G. Friton et al., Berl Münch Tiermaschinemaschineschztl Wschr 116 (2003) pp. 421-426).
  • the problem underlying the present invention was to provide a medication for the prevention or treatment of respiratory diseases in pigs, one of the most important health problems in swine production.
  • meloxicam can be used for the treatment or prevention of respiratory diseases in pigs.
  • the invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in pigs.
  • the invention relates to a method of treating or preventing respiratory diseases in pigs, which method comprises administering an effective amount of meloxicam to the pigs in need thereof.
  • the invention relates to veterinary preparation containing meloxicam as well as at least one antibiotic selected from the group consisting of ⁇ -lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides.
  • Another aspect of the invention is a ready-to-use two-component system for the treatment of respiratory diseases in pigs, wherein:
  • Still another aspect of the invention is an article of manufacture comprising packaging material contained within which is a composition consisting of meloxicam and a pharmaceutically acceptable carrier, and a label which indicates that the composition can be used to treat or prevent respiratory diseases in pigs.
  • FIG. 1 shows the incidence of fever (rectal temperature ⁇ 40.56° C.) in percent following the first treatment in a group of pigs treated with oxytetracycline and meloxicam ( ⁇ ), in a group of pigs treated with oxytetracycline alone ( ⁇ ), and in the untreated control ( ⁇ ).
  • FIG. 2 shows the efficacy of meloxicam in drinking water in reducing lung lesions caused by experimental Swine Influenza Virus (SIV) infection on study days 7 and 14.
  • SIV Swine Influenza Virus
  • the invention relates to the use of meloxicam or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition in a form suitable for systemic or oral administration for the treatment or prevention of respiratory diseases in pigs.
  • Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H- 1,2-benzothiazine-3-carboxamide-1,1-dioxide) of formula is an active substance which belongs to the group of NSAIDs (non-steroidal-anti-inflammatory drugs).
  • NSAIDs non-steroidal-anti-inflammatory drugs.
  • Meloxicam and the sodium and meglumine salt thereof N-methyl-D-glucamine salt
  • EP-A-0 002 482 corresponding to U.S. Pat. No. 4,233,299
  • Meloxicam may be used according to the invention in the form of a physiologically acceptable acid addition salt.
  • physiologically acceptable acid addition salts are meant, according to the invention, the meglumine, sodium, potassium, or ammonium salt, preferably the meloxicam meglumine salt.
  • the pharmaceutical composition is administered corresponding to a daily dose of meloxicam ranging from 0.01 mg/kg to 5.0 mg/kg, preferably from 0.1 mg/kg to 3.5 mg/kg, in particular from 0.2 mg/kg to 2.0 mg/kg.
  • the pharmaceutical composition is preferably administered in a form suitable for injection, in particular for intramuscular injection, or in form of water soluble granules for administration via drinking water or as top dressing on feed.
  • a suitable injection formulation is disclosed, for example, in Example 25 of EP-A-0 002 482.
  • injection solutions may additionally contain excipients selected from among citric acid, lecithin, gluconic acid, tartaric acid, phosphoric acid and EDTA or the salts thereof as disclosed in the Examples 1 to 5 of the International Patent Application WO 01/97813 (corresponding to U.S. Patent App. Pub No. 2002/0035107), each of which is hereby incorporated by reference.
  • an injection solution of meloxicam for needleless injections is disclosed in the International Patent Application WO 03/049733 (corresponding to U.S. Patent App. Pub No. 2003/0119825), each of which is hereby incorporated by reference.
  • Suitable water soluble granules for administration via drinking water or as top dressing on feed are, for example, disclosed in the International Patent Application PCT/EP03/11802 (corresponding to U.S. Patent App. Pub No. 2004/0234596), each of which is hereby incorporated by reference.
  • the meloxicam granules contain a binder which may be selected from among hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatine, starch, and polyethylene glycol ether, preferably hydroxypropylmethylcellulose, polyvinylpyrrolidone, and polyethylene glycol ether, and most preferably hydroxypropylmethylcellulose and polyvinylpyrrolidone.
  • a binder which may be selected from among hydroxypropylmethylcellulose, polyvinylpyrrolidone, gelatine, starch, and polyethylene glycol ether, preferably hydroxypropylmethylcellulose, polyvinylpyrrolidone, and polyethylene glycol ether, and most preferably hydroxypropylmethylcellulose and polyvinylpyrrolidone.
  • meloxicam granules contain a sweetener, which may be selected from among sodium saccharine, aspartame, and SUNETT® (acesulfame K), preferably sodium saccharine or aspartame.
  • a sweetener which may be selected from among sodium saccharine, aspartame, and SUNETT® (acesulfame K), preferably sodium saccharine or aspartame.
  • meloxicam granules containing a flavoring agent which may be selected from among vanilla, honey flavoring, apple flavoring, and contramarum, preferably honey flavoring and apple flavoring.
  • meloxicam granules in which the carrier is selected from among lactose, glucose, mannitol, xylitol, sucrose, and sorbitol, preferably glucose, lactose, or sorbitol, more preferably glucose or lactose, and most preferably glucose.
  • the carrier is selected from among lactose, glucose, mannitol, xylitol, sucrose, and sorbitol, preferably glucose, lactose, or sorbitol, more preferably glucose or lactose, and most preferably glucose.
  • meloxicam granules in which the content of meloxicam is between 0.05% and 4%, preferably between 0.1% and 2%, preferably between 0.3% and 1.8%, more preferably between 0.4% and 1.5%, and most preferably 1.2%. Also particularly preferred are meloxicam granules which contain meglumine and meloxicam in a molar ratio of about 9:8 to 12:8, preferably 10:8.
  • Meloxicam can be used according to the invention to treat or prevent respiratory diseases in any breed of swines.
  • pigs selected from the swine breeds American Landrace, American Yorkshire, Angeln Saddleback, Arapawa Island, Ba Xuyen, Bantu, Bazna, Beijing Black, else Black Pied, Belgian Landrace, Bentheim Black Pied, Berkshire, Black Slavonian, British Landrace, British Lop, Bulgarian White, Cantonese, Chester White, Czech Improved White, Danish Landrace, Dermantsi Pied, Duroc, Dutch Landrace, Fengjing, Finnish Landrace, French Landrace, German Landrace, Gloucestershire Old Spots, Guinea Hog, Hampshire, Hereford, Hezuo, Iberian, Italian Landrace, Jinhua, Kele, Krskopolje, Kunekune, Lacombe, Large Black, Large Black-white, Large White, Lithuanian Native, Mangalitsa, Meishan, Middle White, Minzhu, Mong Cai, Mukota
  • meloxicam is in conjunction with an antibiotic, preferably selected from the group consisting of ⁇ -lactams, quinolones, tetracyclines, sulfonamides, fenicoles, and macrolides. Most preferred are amoxicillin, oxytetracycline, florfenicol, tylosin, tilmicosin, and sulfamethazine.
  • the dose of antibiotic is not critical per se and depends strongly on the different efficacies of the antibiotics used. As a rule up to 150.0 mg/kg, preferably from 0.1 mg/kg to 120 mg/kg, in particular from 10 mg/kg to 110 mg/kg of an antibiotic are co-administered together with meloxicam.
  • Amoxicillin 5 mg/kg to 30 mg/kg, in particular about 10 mg/kg
  • Oxytetracycline 20 mg/kg to 70 mg/kg, in particular about 30 mg/kg
  • Florfenicol 10 mg/kg to 20 mg/kg, in particular about 15 mg/kg
  • Tylosin 10 mg/kg to 25 mg/kg, in particular about 16 mg/kg
  • Tilmicosin 5 mg/kg to 30 mg/kg, in particular 10 mg/kg to 20 mg/kg
  • Sulfamethazine 80 mg/kg to 150 mg/kg, in particular about 100 mg/kg.
  • co-administration in defining use of meloxicam and an antibiotic, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects, in particular, reduction of the symptoms of the respiratory disease in the affected pig of the drug combination.
  • the phrase also is intended to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single capsule or injection solution having a fixed ratio of these active agents or in multiple, separate capsules for each agent.
  • meloxicam and the antibiotic may be co-administered in a combined form, or separately or separately and sequentially wherein the sequential administration is preferably close in time.
  • the medicament according to this invention is used for the prevention or treatment of Porcine Respiratory Disease Complex in growing or fattening pigs; or for the prevention or treatment of respiratory diseases in pigs caused by mycoplasmas, in particular Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, for the prevention or treatment of respiratory diseases in pigs caused by bacteria in particular Actinobacillus spp., in particular Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Arcanobacterium pyogenes, Streptococcus spp., and Staphylococcus spp., or for the prevention or treatment of respiratory diseases in pigs caused by viruses, in particular Swine Influenza Virus, Aujetzky's Virus, Porcine Reproductive and Respiratory Syndrome Virus, Porcine Circovirus, and Transmissible Gastroenteritis and Porcine Respiratory Coronavirus.
  • the medicament according to this invention is used for the prevention or treatment of respiratory diseases in pigs caused by Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella multocida, Streptococcus suis, Swine Influenza Virus, and Porcine Reproductive and Respiratory Syndrome Virus.
  • the study was a controlled, randomized, and blinded exploratory study under experimental conditions with a parallel group design.
  • Crossbred pigs of about 10 weeks of age were challenged with a single intranasal inoculation of Actinobacillus pleuropneumoniae. The next day, pigs were included in the study and treated if they fulfilled the following inclusion criteria: rectal temperature ⁇ 40° C. and clinical symptoms of acute or subacute infectious respiratory disease.
  • the treatment groups were: Group Treatment 1 untreated 2 oxytetracycline 3 oxytetracycline and meloxicam
  • Meloxicam was administered as 0.5% solution, at 0.5 mg/kg daily on three consecutive days, oxytetracycline as 20% long-acting solution (OXYTET® 200) at 20 mg/kg as single injection.
  • the aim of this study was to test the efficacy of meloxicam granules dissolved in drinking water in pigs experimentally infected with Swine Influenza Virus (SIV).
  • the study was an open, negative controlled randomized laboratory study carried out according to GCP at one site.
  • the study animals were clinically examined daily on study days 0 to 7 and 14. They were weighed on study days 7 and 14. All animals of group A and 5 animals of group C were euthanized and necropsied on study day 7; the remaining study animals, group B and 5 study animals of group C, on study day 14.
  • FIG. 2 shows the quantity of lung lesions by lung lobe on study days 7 and 14.
  • meloxicam-treated pigs reached significantly higher weight gains during the two weeks following infection than untreated controls.
  • Mean daily weight gain in the interval study day 0 to 7 was 557 g in meloxicam group A and 257 g in the control (5 study animals of group C).
  • mean daily weight gain was 629 g in meloxicam group B and 486 g in the control (5 study animals of group C).
  • Growth performance data for each group included the Average Daily Gain (ADG) for the following trial periods: d90 to d117, d117 to d170 (slaughtering), and d90 to d170 of age. Mortality was also calculated for these time periods. Slaughterhouse records per group, included the percentage of each lung surface (LS) affected by chronic and acute respiratory lesions.
  • ADG Average Daily Gain
  • RS and AIM in the meloxicam group were significantly lower (p ⁇ 0.05) compared to the control group. Same applies for LS affected by acute lesions (p ⁇ 0.01), while no differences were observed for LS in chronic cases (Table 1).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US11/047,920 2004-02-23 2005-02-01 Meloxicam for the treatment of respiratory diseases in pigs Abandoned US20050187213A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/114,509 US20080280840A1 (en) 2004-02-23 2008-05-02 Meloxicam for the treatment of respiratory diseases in pigs
US14/183,744 US20140179639A1 (en) 2004-02-23 2014-02-19 Meloxicam for the treatment of respiratory diseases in pigs
US15/908,470 US10548901B2 (en) 2004-02-23 2018-02-28 Meloxicam for the treatment of respiratory diseases in pigs
US16/719,681 US11083731B2 (en) 2004-02-23 2019-12-18 Meloxicam for the treatment of respiratory diseases in pigs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04004054A EP1568369A1 (en) 2004-02-23 2004-02-23 Use of meloxicam for the treatment of respiratory diseases in pigs
EP04004054.5 2004-02-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/114,509 Continuation US20080280840A1 (en) 2004-02-23 2008-05-02 Meloxicam for the treatment of respiratory diseases in pigs

Publications (1)

Publication Number Publication Date
US20050187213A1 true US20050187213A1 (en) 2005-08-25

Family

ID=34745861

Family Applications (5)

Application Number Title Priority Date Filing Date
US11/047,920 Abandoned US20050187213A1 (en) 2004-02-23 2005-02-01 Meloxicam for the treatment of respiratory diseases in pigs
US12/114,509 Abandoned US20080280840A1 (en) 2004-02-23 2008-05-02 Meloxicam for the treatment of respiratory diseases in pigs
US14/183,744 Abandoned US20140179639A1 (en) 2004-02-23 2014-02-19 Meloxicam for the treatment of respiratory diseases in pigs
US15/908,470 Expired - Lifetime US10548901B2 (en) 2004-02-23 2018-02-28 Meloxicam for the treatment of respiratory diseases in pigs
US16/719,681 Expired - Fee Related US11083731B2 (en) 2004-02-23 2019-12-18 Meloxicam for the treatment of respiratory diseases in pigs

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/114,509 Abandoned US20080280840A1 (en) 2004-02-23 2008-05-02 Meloxicam for the treatment of respiratory diseases in pigs
US14/183,744 Abandoned US20140179639A1 (en) 2004-02-23 2014-02-19 Meloxicam for the treatment of respiratory diseases in pigs
US15/908,470 Expired - Lifetime US10548901B2 (en) 2004-02-23 2018-02-28 Meloxicam for the treatment of respiratory diseases in pigs
US16/719,681 Expired - Fee Related US11083731B2 (en) 2004-02-23 2019-12-18 Meloxicam for the treatment of respiratory diseases in pigs

Country Status (16)

Country Link
US (5) US20050187213A1 (uk)
EP (2) EP1568369A1 (uk)
JP (1) JP5009147B2 (uk)
KR (1) KR101233359B1 (uk)
CN (1) CN1921865B (uk)
AU (1) AU2005215122B2 (uk)
BR (1) BRPI0507966A (uk)
CA (1) CA2554040C (uk)
DK (1) DK1720554T3 (uk)
ES (1) ES2394038T3 (uk)
MX (1) MXPA06009575A (uk)
RU (1) RU2360680C2 (uk)
SG (1) SG150531A1 (uk)
TW (1) TW200533362A (uk)
UA (1) UA92584C2 (uk)
WO (1) WO2005079806A1 (uk)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180092A1 (en) * 2002-10-25 2004-09-16 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20050245510A1 (en) * 2004-04-29 2005-11-03 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam formulations in veterinary medicine
US20050288280A1 (en) * 2004-06-23 2005-12-29 Boehringer Ingelheim Vetmedica Gmbh Meloxicam in veterinary medicine
US20060079516A1 (en) * 2000-06-20 2006-04-13 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
KR100643222B1 (ko) 2005-09-01 2006-11-10 빙빙투기술 주식회사 이유후 전신소모성 증후군 치료용 조성물
US20070077296A1 (en) * 2005-09-30 2007-04-05 Folger Martin A Pharmaceutical Preparation containing Meloxicam
US20080132493A1 (en) * 2001-12-12 2008-06-05 Martin Andreas Folger Highly concentrated stable meloxicam solutions for needleless injection
US20080280840A1 (en) * 2004-02-23 2008-11-13 Boehringer Ingelheim Vetmedica, Gmbh Meloxicam for the treatment of respiratory diseases in pigs
KR100870077B1 (ko) 2006-10-27 2008-11-25 권영득 이유후 전신소모성증후군(ｐｍｗｓ)의 치료용 복합제조성물
US20090081202A1 (en) * 2007-08-27 2009-03-26 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US20090098527A1 (en) * 2006-09-12 2009-04-16 Fischer Gerald W Biological organism identification product and methods
US20090197874A1 (en) * 2006-06-15 2009-08-06 Alpex Pharma Sa Solid forms containing meloxicam with improved buccal taste and process for their preparation
US20090312285A1 (en) * 2007-10-01 2009-12-17 Longhorn Vaccines & Diagnostics, Llc Biological specimen collection and transport system and methods of use
US20100009343A1 (en) * 2006-09-12 2010-01-14 Longhorn Vaccines & Diagnostics, Llc Compositions and method for rapid, real-time detection of influenza a virus (h1n1) swine 2009
US20110083985A1 (en) * 2009-10-12 2011-04-14 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US20110092454A1 (en) * 2009-09-30 2011-04-21 Dean Rimoldi Methods For Treating Mycoplasma Related Conditions In Livestock
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
WO2012009542A3 (en) * 2010-07-14 2014-03-27 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0700969A (pt) 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
GB2520065A (en) * 2013-11-08 2015-05-13 Norbrook Lab Ltd Tulathromycin and nonsteroidal anti-inflammatory drug compositions
EP2995297A1 (fr) * 2014-09-09 2016-03-16 Ceva Sante Animale Compositions parentérales et leurs utilisations
EP3656400A4 (en) * 2017-07-20 2021-10-20 National University Corporation Hokkaido University COMBINATION OF INHIBITOR AGAINST PD-1 / PD-L1 AND COX-2 INHIBITOR
EP4098265A4 (en) * 2020-01-30 2024-03-13 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. USE OF ACYLATED SPIRAMYCIN FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CORONAVIRUS INFECTIOUS DISEASES

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233299A (en) * 1977-12-16 1980-11-11 Boehringer Ingelheim Gmbh 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides and salts thereof
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
US6284269B1 (en) * 1997-08-27 2001-09-04 Hexal Ag Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6319519B2 (en) * 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020099049A1 (en) * 1997-09-17 2002-07-25 Burch Ronald M. Analgesic combination of oxycodone and meloxicam
US20020187187A1 (en) * 2001-04-21 2002-12-12 Toshimitsu Ohki Fast disintegrating meloxicam tablet
US20030109701A1 (en) * 2001-12-11 2003-06-12 Laura Coppi Crystalline forms of meloxicam and processes for their preparation and interconversion
US20030119825A1 (en) * 2001-12-12 2003-06-26 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US6599529B1 (en) * 1997-09-11 2003-07-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
US20040001883A1 (en) * 2002-03-30 2004-01-01 Boehringer Ingelheim International Gmbh Meloxicam suppositories
US20040043992A1 (en) * 2002-05-22 2004-03-04 Boehringer Ingelheim International Gmbh Meloxicam for alleviating organ injury during organ operation or transplantation
US20040110747A1 (en) * 2002-12-06 2004-06-10 Boehringer Ingelheim International Gmbh Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US20040171611A1 (en) * 2002-09-30 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline acetic acid solvate of meloxicam
US20040180092A1 (en) * 2002-10-25 2004-09-16 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules

Family Cites Families (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2795529A (en) * 1954-06-17 1957-06-11 American Home Prod Stabilized hyaluronidase solution containing calcium chloride
US3089818A (en) 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US3288675A (en) * 1964-03-20 1966-11-29 Hoffmann La Roche Parenteral sulfonamide compositions and processes
JPS477352Y1 (uk) 1969-06-13 1972-03-17
BE789726A (fr) * 1971-10-06 1973-04-05 Merck & Co Inc Suppositoires a l'indomethacine
US3931212A (en) * 1973-07-19 1976-01-06 Warner-Lambert Company Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives
US3947576A (en) * 1973-09-27 1976-03-30 Mortell Company Synergistic biostatic composition
JPS52102416A (en) 1976-02-19 1977-08-27 Okawara Mfg Granule making method of herb medicine and like
FR2437838A1 (fr) 1978-07-25 1980-04-30 Roecar Holdings Nv Medicament pour le traitement de l'adenome benin de la prostate
IE49770B1 (en) 1979-05-21 1985-12-11 Leo Pharm Prod Ltd 6beta-halopenicillanic acid derivatives
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
IE51846B1 (en) 1980-11-17 1987-04-15 Leo Pharm Prod Ltd Pharmaceutical preparation for veterinary use and an appliance containing it
DE3217315C2 (de) 1982-05-08 1986-05-22 Gödecke AG, 1000 Berlin Arzneimittelzubereitungen mit einem Gehalt an Oxicam-Derivaten
US4447443A (en) 1982-11-15 1984-05-08 Merck & Co., Inc. Anti-inflammatory/analgesic combination of α-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID)
EP0127400A3 (en) 1983-05-31 1986-06-11 Stauffer Chemical Company Magnesium oxide containing vehicle for direct compression tableting
US4543200A (en) * 1983-09-28 1985-09-24 Sherman Laboratories, Inc. Contact lens preservative system cleaner and method
IT1212778B (it) 1983-10-07 1989-11-30 Lisapharma Spa Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
AU573321B2 (en) * 1984-03-14 1988-06-02 Jerome Corbiere Process for solubilizing active principles and pharmaceuticalcompositions thus obtained
JPH0753663B2 (ja) 1984-10-09 1995-06-07 武田薬品工業株式会社 チアミン塩の顆粒，その製造法および錠剤
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
IT1196307B (it) 1984-10-22 1988-11-16 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam monoidrato
US4687662A (en) 1985-08-30 1987-08-18 Warner-Lambert Company Therapeutic effervescent composition
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
NL8600731A (nl) * 1986-03-21 1987-10-16 Dmv Campina Bv Verbeterde gesproeidroogde lactose en werkwijze ter bereiding ervan.
SE8605515D0 (sv) 1986-12-22 1986-12-22 Astra Laekemedel Ab A liquid dosage form for oral administration of a pharmaceutically active substance
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4835187A (en) * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
IL83086A (en) 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
CA1328614C (en) 1987-09-11 1994-04-19 Cherng-Chyi Roger Fu Preservative system for ophthalmics formulations
IT1216686B (it) * 1988-04-01 1990-03-08 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
ATE103599T1 (de) 1988-09-21 1994-04-15 Searle & Co 3-oxiranbenzoesaeuren und derivate.
ATE107854T1 (de) 1988-09-30 1994-07-15 Rhone Poulenc Rorer Ltd Pharmazeutisches granulat.
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IL95942A0 (en) 1989-10-13 1991-07-18 Syntex Inc Collagen-containing ophthalmic formulation
KR920002148A (ko) 1990-07-03 1992-02-28 안드레아 엘. 콜비 비스테로이드계 소염제에 의해 유발된 위장 증상을 완화시키기 위한 약제 조성물 및 이를 완화시키는 방법
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
HU205550B (en) * 1990-11-27 1992-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pyroxycam solution of increased stability, free from effects damaging tussues
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
UA37214C2 (uk) 1991-01-30 2001-05-15 Дзе Веллкам Фаундейшн Лімітед Таблетки, що диспергуються у воді, та спосіб їх виготовлення
JP3541849B2 (ja) 1991-04-19 2004-07-14 久光製薬株式会社 消炎鎮痛貼付剤
FR2679135B1 (fr) 1991-07-18 1995-05-19 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a adhesivite amelioree et leurs procedes de preparation.
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
IT1251650B (it) 1991-10-29 1995-05-17 Boehringer Ingelheim Italia Composti in incusione di meloxicam con ciclodestrine
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
JP2860729B2 (ja) 1992-03-10 1999-02-24 エスエス製薬株式会社 プラノプロフェン懸濁シロップ剤
DE4217971C1 (de) 1992-05-30 1993-10-21 Boehringer Ingelheim Vetmed Verfahren und Wirbelbettapparatur zum Granulieren und/oder Umhüllen
US5455271A (en) 1992-06-18 1995-10-03 The Scripps Research Institute Tight-binding inhibitors of leukotriene A4 hydrolase
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US5304561A (en) * 1992-07-24 1994-04-19 Faezeh Sarfarazi New concept in glaucoma treatment
KR0169505B1 (ko) 1992-09-11 1999-01-15 오오쓰끼 아끼히꼬 약제 포장용 폴리올레핀 포장재, 그의 제조방법 및 약제 포장용 용기
US5380934A (en) * 1992-10-29 1995-01-10 Kyowa Hakko Kogyo Co., Ltd. Process for producing alanylgutamine
JPH06157312A (ja) 1992-11-12 1994-06-03 Shionogi & Co Ltd 苦味改善テルフェナジンドライシロップ顆粒剤
IT1264020B (it) 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
ES2065846B1 (es) 1993-04-20 1995-10-01 Cusi Lab Formulacion farmaceutica a base de un agente antiinflamatorio esteroidico o no esteroidico y un antibiotico pertenciente al grupo de los inhibidores de la adn girasa para su utilizacion topica oftalmica.
DE4322826A1 (de) 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5676944A (en) 1993-10-06 1997-10-14 The Regents Of The University Of California Ocular therapy with homologous macrophages
US5474985A (en) 1993-12-22 1995-12-12 The Regents Of The University Of California Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
AU1249395A (en) 1994-01-11 1995-08-01 Ciba-Geigy Ag Topical treatment of ocular photophobia
EP0708646A1 (en) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
JP3550782B2 (ja) 1995-03-14 2004-08-04 大日本インキ化学工業株式会社 乳酸系ポリエステルの発泡性粒子
US5674888A (en) 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
US5599535A (en) 1995-06-07 1997-02-04 Regents Of The University Of California Methods for the cyto-protection of the trabecular meshwork
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
JPH0912426A (ja) 1995-06-29 1997-01-14 Asahi Chem Ind Co Ltd 吸湿性物質組成物
WO1997003667A1 (en) 1995-07-19 1997-02-06 Merck & Co., Inc. Method of treating colonic adenomas
EP0839029A1 (en) 1995-07-20 1998-05-06 PHARMACIA & UPJOHN COMPANY Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
FR2739562B1 (fr) 1995-10-09 1998-04-24 Moreau Defarges Alain Dispositif d'injection par jet sans aiguille, comportant une cartouche surmoulee
WO1997017978A1 (en) 1995-11-13 1997-05-22 Pitmy International N.V. Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
US5686414A (en) 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
DK0888127T3 (da) 1996-02-13 2002-04-08 Searle & Co Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer
WO1997031631A1 (en) 1996-02-27 1997-09-04 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
US6048557A (en) 1996-03-26 2000-04-11 Dsm N.V. PUFA coated solid carrier particles for foodstuff
DE69711661T2 (de) * 1996-06-20 2002-10-17 Novartis Ag, Basel Micrococcin antibiotika zur prävention und therapie der mastitis
EP0918513B1 (de) * 1996-08-15 2000-12-06 Losan Pharma GmbH Gut schluckbare orale arzneiform
ATA156496A (de) 1996-09-03 1997-10-15 Nycomed Austria Gmbh Pharmazeutische zusammensetzung
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
GB2318511A (en) 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
DK0950059T3 (da) 1997-01-06 2004-11-01 Pfizer Cycliske sulfonderivater
CN1062161C (zh) 1997-01-08 2001-02-21 大连弘丰制药厂 制备稳定灯盏花素注射液的方法
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5954104A (en) 1997-02-28 1999-09-21 Abbott Laboratories Container cap assembly having an enclosed penetrator
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
IL129575A (en) 1997-03-26 2004-06-20 Janssen Pharmaceutica Nv Pills with a core coated with a fungicide and polymer
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
TR199902748T2 (xx) 1997-05-06 2000-05-22 Norbrook Laboratories Limited Uzun s�re etkili antimikrobik maddelerle ilgili geli�meler
FR2765898B1 (fr) * 1997-07-10 1999-10-01 Thibierge Et Comar Papier calque de couleur
DE19729879C2 (de) 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
JP4936579B2 (ja) 1997-09-05 2012-05-23 第一三共株式会社 ロキソプロフェン含有医薬製剤
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
GB9726701D0 (en) 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use
TW492882B (en) * 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
PT1035835E (pt) 1997-12-03 2003-12-31 Merck & Co Inc Formulacoes injectaveis de accao prolongada contendo oleo de ricino hidrogenado
WO1999039730A1 (en) 1998-02-09 1999-08-12 Kaken Pharmaceutical Co., Ltd. Oral preparations containing peptides promoting the secretion of growth hormone
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
EP0945131A1 (de) 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Perorale Wirkstoff-Suspension
EP0945134A1 (de) 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation
PT1082109E (pt) 1998-04-29 2004-10-29 Sumitomo Pharma Formulacao oral que compreende biguanidina e um acido organico
AU754064B2 (en) * 1998-05-15 2002-11-07 Wakamoto Pharmaceutical Co., Ltd. Anti-inflammatory eye drops
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
PT1109534E (pt) 1998-09-10 2003-06-30 Nycomed Danmark As Composicoes farmaceuticas de farmacos de libertacao rapida
DE19847968A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6156349A (en) * 1998-12-14 2000-12-05 Steinbach, Pylant And Herman, L.L.C. Method of treating HIV infection with suppository containing mammalian liver extract
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
FR2796840B1 (fr) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US6166012A (en) * 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
US6552020B1 (en) 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
AU765526B2 (en) 1999-08-17 2003-09-18 Novartis Consumer Health S.A. Rapidly dissolving dosage form and process for making same
FR2798289B1 (fr) * 1999-09-15 2004-12-31 Cll Pharma Formes galeniques a delitement rapide en bouche et leur procede de preparation
WO2001037838A1 (en) 1999-11-24 2001-05-31 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
US6685928B2 (en) * 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
KR200182299Y1 (ko) 1999-12-08 2000-05-15 장지일 플로스 케이스를 포함하는 플로스 홀더
JP2001172183A (ja) 1999-12-21 2001-06-26 Wakamoto Pharmaceut Co Ltd 眼科用医薬組成物
IN191512B (uk) 2000-01-21 2003-12-06 Panacea Biotech
DE10010123A1 (de) 2000-03-03 2001-09-20 Boehringer Ingelheim Int Nadelloser Injektor in Miniaturausführung
US6689092B2 (en) 2000-03-03 2004-02-10 Boehringer International Gmbh Needle-less injector of miniature type
JP5162071B2 (ja) * 2000-05-03 2013-03-13 ドシルバ，ジヨー 液体投与調合物を製造する方法および装置
US20020016342A1 (en) * 2000-05-15 2002-02-07 Edward Scolnick Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor
DE10024752A1 (de) 2000-05-16 2001-11-29 Ben Pfeifer Mittel und Vorrichtung zur Behandlung von Prostata-Erkrankungen
WO2001089519A1 (en) * 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
DE10030345A1 (de) 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen
DE10032132A1 (de) 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
CA2415697A1 (en) * 2000-07-13 2002-01-24 James C. Forbes Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
GB0022215D0 (en) 2000-09-11 2000-10-25 Boehringer Ingelheim Pharma Method for the treatment of thromboembolic disorders in patients with aspirin« resistance
US6787568B1 (en) 2000-11-27 2004-09-07 Phoenix Scientific, Inc. Antibiotic/analgesic formulation and a method of making this formulation
EP1350262B8 (en) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
DE10300323A1 (de) 2003-01-09 2004-10-14 Baxter Healthcare S.A. Sicherheitsbehälter mit erhöhter Bruch und Splitterfestigkeit sowie kontaminationsfreier Außenfläche für biologisch aktive Substanzen und Verfahren zu deren Herstellung
US20040204413A1 (en) * 2001-01-26 2004-10-14 Joaquina Faour Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant
US6995190B2 (en) 2001-03-09 2006-02-07 Veterinary Solutions Method and treatment with ketoprofen solution
AU2002306868A1 (en) * 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
EP1250921A1 (en) 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
AUPR527801A0 (en) 2001-05-25 2001-06-21 University Of Sydney, The Animal husbandry iii
JP2005534279A (ja) * 2001-09-28 2005-11-17 ブリガム ヤング ユニバーシティ 新規なシクロオキシゲナーゼ変異体とその使用方法
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
EP1348436A1 (en) 2002-03-30 2003-10-01 Boehringer Ingelheim International GmbH Meloxicam suppositories
US20040024042A1 (en) * 2002-04-02 2004-02-05 Vanderbilt University COX2 inhibition in the prevention and treatment of autosomal dominant polycystic kidney disease
WO2004004776A1 (en) 2002-07-09 2004-01-15 B.M.R.A. Corporation B.V. Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
WO2004026313A1 (en) 2002-09-17 2004-04-01 Nippon Boehringer Ingelheim Co., Ltd. Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
WO2004026116A2 (en) 2002-09-19 2004-04-01 The Regents Of The University Of California Use of etodoclac to treat hyperplasia
DE10250081A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Wasserlösliche Meloxicam Granulate
US20050197332A1 (en) * 2002-12-10 2005-09-08 Boehringer Ingelheim International Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US20040170687A1 (en) 2003-02-27 2004-09-02 Integrity Pharmaceutical Corporation Compositions with improved stability and methods of formulation thereof
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
WO2004078113A2 (en) * 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040198826A1 (en) * 2003-04-07 2004-10-07 Boehringer Ingelheim International Gmbh Pharmaceutical combination for treating benign prostatic hyperplasia or for treating abacterial prostatitis
DE10315702A1 (de) 2003-04-07 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Arzneitmittelkombinationen zur Behandlung von gutartiger Prostatahyperplasie oder zur Behandlung von abakterieller Prostatitis
JP4018022B2 (ja) 2003-04-10 2007-12-05 株式会社ホシモト 開閉用ハンドル装置
WO2004103283A2 (en) 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
AR044437A1 (es) * 2003-05-29 2005-09-14 Schering Plough Ltd Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino
US20050038018A1 (en) * 2003-07-09 2005-02-17 Boehringer Ingelheim International Gmbh Meloxicam compositions
WO2005004915A2 (en) 2003-07-09 2005-01-20 Boehringer Ingelheim International Gmbh Compositions comprising meloxicam
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
CN1233323C (zh) 2003-12-09 2005-12-28 成都圣诺科技发展有限公司 美洛昔康口腔崩解片及其制备方法
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20070193894A1 (en) 2004-04-08 2007-08-23 Idd-Eal Manufacturing Company Limited Container for constituting a formulation in liquid form
DE102004021281A1 (de) 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004025324A1 (de) 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung
DE102004030409A1 (de) 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
RS52057B2 (sr) 2004-08-13 2018-03-30 Boehringer Ingelheim Int Formulacija tablete sa produženim oslobađanjem koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu so
PL1824493T3 (pl) 2004-12-06 2009-01-30 Janssen Pharmaceutica Nv Zawiesina zawierająca meloksykam do podawania doustnego
JP2008534473A (ja) * 2005-03-23 2008-08-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トロンボキサン受容体拮抗薬及びトロンボキサンシンターゼ阻害薬の組み合わせ及びｃｏｘ−２阻害薬を含む組成物
NZ567627A (en) * 2005-09-30 2011-08-26 Boehringer Ingelheim Vetmed Granulation process for making a divisible tablet containing meloxicam
ATE459686T1 (de) 2005-12-20 2010-03-15 Basell Poliolefine Srl Polypropylenzusammensetzungen für gestreckte artikel
US20070187405A1 (en) 2006-01-23 2007-08-16 Pujara Chetan P Container for compositions containing cefdinir
JP4965130B2 (ja) 2006-01-26 2012-07-04 日本臓器製薬株式会社 乾式直打速崩壊性錠剤
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
ITMI20060983A1 (it) 2006-05-18 2007-11-19 Formevet S P A Composizioni farmaceutiche veterinarie per il trattamento del dolore e dell'inifiamazione
EP2117506A2 (en) 2006-12-13 2009-11-18 Stephen M. Tuel Methods of making pharmaceutical components for customized drug products
BRPI0700969A (pt) 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
JP4321624B2 (ja) 2007-05-21 2009-08-26 株式会社デンソー 半導体素子駆動回路
FR2917381B1 (fr) 2007-06-15 2009-10-16 Ceva Sante Animale Sa Conditionnement plastique multicouche pour la conservation d'une composition pharmaceutique
MX2010003935A (es) 2007-10-12 2010-09-24 Map Pharmaceuticals Inc Suministro de farmaco por inhalacion.
GB0724707D0 (en) 2007-12-19 2008-01-30 Burke Michael H A process for the preparation of an orally administered unit dose tablet
DK4378443T3 (da) 2009-10-12 2025-08-18 Boehringer Ingelheim Vetmedica Gmbh Beholdere til sammensætninger, der omfatter meloxicam
SG183846A1 (en) 2010-03-03 2012-10-30 Boehringer Ingelheim Vetmed Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US20110218191A1 (en) 2010-03-03 2011-09-08 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long term-treatment of kidney disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233299A (en) * 1977-12-16 1980-11-11 Boehringer Ingelheim Gmbh 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxides and salts thereof
US6284269B1 (en) * 1997-08-27 2001-09-04 Hexal Ag Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6599529B1 (en) * 1997-09-11 2003-07-29 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (NSAIDs)
US20020099049A1 (en) * 1997-09-17 2002-07-25 Burch Ronald M. Analgesic combination of oxycodone and meloxicam
US6682747B1 (en) * 1998-03-27 2004-01-27 Boehringer Ingelheim Pharma Kg Process for preparing an oral suspension of a pharmaceutical substance
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
US6319519B2 (en) * 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020187187A1 (en) * 2001-04-21 2002-12-12 Toshimitsu Ohki Fast disintegrating meloxicam tablet
US20040234596A1 (en) * 2001-04-21 2004-11-25 Boehringer Ingelheim International Gmbh Fast disintegrating meloxicam tablet
US20030109701A1 (en) * 2001-12-11 2003-06-12 Laura Coppi Crystalline forms of meloxicam and processes for their preparation and interconversion
US20030119825A1 (en) * 2001-12-12 2003-06-26 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US20040001883A1 (en) * 2002-03-30 2004-01-01 Boehringer Ingelheim International Gmbh Meloxicam suppositories
US20040043992A1 (en) * 2002-05-22 2004-03-04 Boehringer Ingelheim International Gmbh Meloxicam for alleviating organ injury during organ operation or transplantation
US20040171611A1 (en) * 2002-09-30 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline acetic acid solvate of meloxicam
US20040180092A1 (en) * 2002-10-25 2004-09-16 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040110747A1 (en) * 2002-12-06 2004-06-10 Boehringer Ingelheim International Gmbh Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993557B2 (en) 2000-06-20 2018-06-12 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US20060079516A1 (en) * 2000-06-20 2006-04-13 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US9956288B2 (en) 2000-06-20 2018-05-01 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions
US20080132493A1 (en) * 2001-12-12 2008-06-05 Martin Andreas Folger Highly concentrated stable meloxicam solutions for needleless injection
US8920820B2 (en) 2001-12-12 2014-12-30 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US10098891B2 (en) 2001-12-12 2018-10-16 Boehringer Ingelheim Vetmedica Gmbh Highly concentrated stable meloxicam solutions for needleless injection
US20040180092A1 (en) * 2002-10-25 2004-09-16 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US9066955B2 (en) 2002-10-25 2015-06-30 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US11083731B2 (en) 2004-02-23 2021-08-10 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs
US20080280840A1 (en) * 2004-02-23 2008-11-13 Boehringer Ingelheim Vetmedica, Gmbh Meloxicam for the treatment of respiratory diseases in pigs
US10548901B2 (en) 2004-02-23 2020-02-04 Boehringer Ingelheim Vetmedica Gmbh Meloxicam for the treatment of respiratory diseases in pigs
US20050245510A1 (en) * 2004-04-29 2005-11-03 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam formulations in veterinary medicine
US20050288280A1 (en) * 2004-06-23 2005-12-29 Boehringer Ingelheim Vetmedica Gmbh Meloxicam in veterinary medicine
KR100643222B1 (ko) 2005-09-01 2006-11-10 빙빙투기술 주식회사 이유후 전신소모성 증후군 치료용 조성물
US20070077296A1 (en) * 2005-09-30 2007-04-05 Folger Martin A Pharmaceutical Preparation containing Meloxicam
US20090197874A1 (en) * 2006-06-15 2009-08-06 Alpex Pharma Sa Solid forms containing meloxicam with improved buccal taste and process for their preparation
US10016359B2 (en) * 2006-06-15 2018-07-10 Alpex Pharma Sa Solid forms containing meloxicam with improved buccal taste and process for their preparation
US20100009343A1 (en) * 2006-09-12 2010-01-14 Longhorn Vaccines & Diagnostics, Llc Compositions and method for rapid, real-time detection of influenza a virus (h1n1) swine 2009
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US20090098527A1 (en) * 2006-09-12 2009-04-16 Fischer Gerald W Biological organism identification product and methods
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US9080204B2 (en) 2006-09-12 2015-07-14 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
KR100870077B1 (ko) 2006-10-27 2008-11-25 권영득 이유후 전신소모성증후군(ｐｍｗｓ)의 치료용 복합제조성물
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US8821885B2 (en) 2007-08-27 2014-09-02 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US10596250B2 (en) 2007-08-27 2020-03-24 Longhorn Vaccines And Diagnostics, Llc Methods of treating and preventing influenza infections
US20090081202A1 (en) * 2007-08-27 2009-03-26 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US9777045B2 (en) 2007-08-27 2017-10-03 Longhorn Vaccines And Diagnostics, Llc Immunogenic compositions and methods
US9388220B2 (en) 2007-08-27 2016-07-12 Longhorn Vaccines And Diagnostics, Llc Immunogenic compositions and methods
US20090312285A1 (en) * 2007-10-01 2009-12-17 Longhorn Vaccines & Diagnostics, Llc Biological specimen collection and transport system and methods of use
US8293467B2 (en) 2007-10-01 2012-10-23 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US9416416B2 (en) 2007-10-01 2016-08-16 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection/transport compositions and methods
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8084443B2 (en) 2007-10-01 2011-12-27 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US9212399B2 (en) 2007-10-01 2015-12-15 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and method of use
US8415330B2 (en) 2007-10-01 2013-04-09 Longhorn Vaccines & Diagnostics, Llc Biological specimen collection and transport system and method of use
US8669240B2 (en) 2007-10-01 2014-03-11 Longhorn Vaccines & Diagnostics, Llc Biological specimen collection and transport system and method of use
US20110092454A1 (en) * 2009-09-30 2011-04-21 Dean Rimoldi Methods For Treating Mycoplasma Related Conditions In Livestock
US9101529B2 (en) 2009-10-12 2015-08-11 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9186296B2 (en) 2009-10-12 2015-11-17 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US20110083985A1 (en) * 2009-10-12 2011-04-14 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
US9149480B2 (en) 2010-03-03 2015-10-06 Boehringer Ingeleheim Vetmedica GmbH Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9943486B2 (en) 2010-05-05 2018-04-17 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US8791105B2 (en) 2010-07-14 2014-07-29 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
WO2012009542A3 (en) * 2010-07-14 2014-03-27 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
US9598462B2 (en) 2012-01-26 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
US10087439B1 (en) 2015-05-14 2018-10-02 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples

Also Published As

Publication number Publication date
CN1921865B (zh) 2010-06-16
JP5009147B2 (ja) 2012-08-22
CA2554040C (en) 2014-08-05
AU2005215122A1 (en) 2005-09-01
US20140179639A1 (en) 2014-06-26
WO2005079806A1 (en) 2005-09-01
US10548901B2 (en) 2020-02-04
SG150531A1 (en) 2009-03-30
EP1720554B1 (en) 2012-07-18
MXPA06009575A (es) 2007-03-15
KR101233359B1 (ko) 2013-02-13
US20200121692A1 (en) 2020-04-23
RU2006133829A (ru) 2008-03-27
BRPI0507966A (pt) 2007-07-17
US20080280840A1 (en) 2008-11-13
KR20070033960A (ko) 2007-03-27
UA92584C2 (uk) 2010-11-25
US11083731B2 (en) 2021-08-10
US20180185380A1 (en) 2018-07-05
CA2554040A1 (en) 2005-09-01
AU2005215122B2 (en) 2011-08-11
CN1921865A (zh) 2007-02-28
DK1720554T3 (da) 2012-10-15
EP1568369A1 (en) 2005-08-31
RU2360680C2 (ru) 2009-07-10
ES2394038T3 (es) 2013-01-16
TW200533362A (en) 2005-10-16
EP1720554A1 (en) 2006-11-15
JP2007523205A (ja) 2007-08-16

Similar Documents

Publication Publication Date Title
US11083731B2 (en) Meloxicam for the treatment of respiratory diseases in pigs
CN110869028B (zh) 治疗猫冠状病毒感染的方法
EP1462101B1 (en) Drinkable preparation comprising ketoprofen and use thereof in the simultaneous treatment of a group of animals of respiratory diseases
Wilson Rational selection of antimicrobials for use in horses
EP2293777B1 (en) Pharmaceutical transdermal compositions and method for treating inflammation in cattle
Schuller et al. Long-term outcomes in dogs with sinonasal aspergillosis treated with intranasal infusions of enilconazole
US7910620B2 (en) Uses of neuraminidase inhibitors in infectious diseases
JP5322649B2 (ja) セフキノム組成物およびその使用方法
Claerhout Managing Actinobacillus pleuropneumoniae infections.
Visser Antimicrobial Therapy in Companion Birds
US20130005804A1 (en) Novel Uses of Neuraminidase Inhibitors in Infectious Diseases
Wormer Diagnosis: HELMINTHIASIS Prescription

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANG, INGO;PAPATSAS, IOANNIS;REEL/FRAME:016093/0958;SIGNING DATES FROM 20050330 TO 20050404

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION